{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:38:17Z","timestamp":1788777497816,"version":"build-2803163510"},"reference-count":43,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>von Willebrand disease (VWD), the most common inherited bleeding disorder in the U.S. population, is caused by defects in the expression and processing of von Willebrand factor (VWF), a blood glycoprotein required for normal hemostasis that mediates the adhesion of platelets to sites of vascular damage by binding to specific platelet glycoproteins and to constituents of exposed connective tissue. To assess whether VWF deficiency can be corrected by gene transfer, a plasmid expressing the intact 8.4-kb murine VWF coding sequence, directed by the cyto-megalovirus immediate\/early promoter\/enhancer, was delivered through hydrodynamic tail vein injection into VWF knockout mice (VWF\u2013\/\u2013) that exhibit defects in hemostasis, including highly prolonged bleeding time and spontaneous bleeding events, closely mimicking severe human VWD. VWF antigen levels in plasma from animals receiving VWF cDNA, but not control animals, revealed normalized levels of circulating VWF that persisted for at least 1 week after injection. Western blot analysis of plasma from animals receiving VWF cDNA, but not control animals, revealed high molecular\u2013weight multimers with patterns similar to those observed in wild-type mice. Reverse transcription\u2013polymerase chain reaction (RT-PCR) on RNA isolated from the livers of animals receiving VWF cDNA, but not control animals, demonstrated that VWF was expressed in the liver, and immunohistochemical analysis of the livers of treated VWF\u2013\/\u2013 mice revealed VWF-specific staining throughout the liver parenchyma but not in endothelial cells. Plasma from treated VWF\u2013\/\u2013 mice, but not control VWF\u2013\/\u2013 mice, supported the hypothesis that murine platelets aggregate in the presence of botrocetin. Although levels of circulating factor VIII in untreated VWF\u2013\/\u2013 mice were less than 10% those in wild-type mice, levels of factor VIII in VWF\u2013\/\u2013 animals treated with VWF cDNA, but not in control animals, were normalized to values in wild-type mice, indicating the restoration of factor VIII carrier function for VWF in treated mice that persisted for at least 1 week at higher doses of VWF cDNA. Most important, bleeding time was normalized by 48 hours after the delivery of VWF cDNA, but not by the control plasmid. These data suggest that with the use of gene transfer of VWF cDNA, VWF protein can be expressed, processed, and secreted in a physiologically active form; thus, it may be possible to correct VWD using gene transfer.<\/jats:p>","DOI":"10.1182\/blood-2005-06-2330","type":"journal-article","created":{"date-parts":[[2006,4,26]],"date-time":"2006-04-26T04:14:16Z","timestamp":1146024856000},"page":"862-869","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Correction of a murine model of von Willebrand disease by gene transfer"],"prefix":"10.1182","volume":"108","author":[{"given":"Robert G.","family":"Pergolizzi","sequence":"first","affiliation":[{"name":"From the Departments of Genetic Medicine and Pediatrics, Weill Medical College of Cornell University, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangchun","family":"Jin","sequence":"additional","affiliation":[{"name":"From the Departments of Genetic Medicine and Pediatrics, Weill Medical College of Cornell University, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Chan","sequence":"additional","affiliation":[{"name":"From the Departments of Genetic Medicine and Pediatrics, Weill Medical College of Cornell University, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Pierre","sequence":"additional","affiliation":[{"name":"From the Departments of Genetic Medicine and Pediatrics, Weill Medical College of Cornell University, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Bussel","sequence":"additional","affiliation":[{"name":"From the Departments of Genetic Medicine and Pediatrics, Weill Medical College of Cornell University, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Ferris","sequence":"additional","affiliation":[{"name":"From the Departments of Genetic Medicine and Pediatrics, Weill Medical College of Cornell University, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip L.","family":"Leopold","sequence":"additional","affiliation":[{"name":"From the Departments of Genetic Medicine and Pediatrics, Weill Medical College of Cornell University, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald G.","family":"Crystal","sequence":"additional","affiliation":[{"name":"From the Departments of Genetic Medicine and Pediatrics, Weill Medical College of Cornell University, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111712054456300_REF1","doi-asserted-by":"crossref","unstructured":"Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood. 1987;69: 454-459.","DOI":"10.1182\/blood.V69.2.454.454"},{"key":"2019111712054456300_REF2","doi-asserted-by":"crossref","unstructured":"Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr. 1993;123: 893-898.","DOI":"10.1016\/S0022-3476(05)80384-1"},{"key":"2019111712054456300_REF3","doi-asserted-by":"crossref","unstructured":"Nichols WC, Ginsburg D. von Willebrand disease. Medicine (Baltimore). 1997;76: 1-20.","DOI":"10.1097\/00005792-199701000-00001"},{"key":"2019111712054456300_REF4","doi-asserted-by":"crossref","unstructured":"Mohlke KL, Nichols WC, Ginsburg D. The molecular basis of von Willebrand disease. Int J Clin Lab Res. 1999;29: 1-7.","DOI":"10.1007\/s005990050054"},{"key":"2019111712054456300_REF5","doi-asserted-by":"crossref","unstructured":"Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med. 2004;351: 683-694.","DOI":"10.1056\/NEJMra040403"},{"key":"2019111712054456300_REF6","doi-asserted-by":"crossref","unstructured":"Sadler JE. New concepts in von Willebrand disease. Annu Rev Med. 2005;56: 173-191.","DOI":"10.1146\/annurev.med.56.082103.104713"},{"key":"2019111712054456300_REF7","unstructured":"Johns Hopkins University. Von Willebrand disease. OMIM: online Mendelian inheritance in man. Available at: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/dispomim. Accessed May 26, 2005."},{"key":"2019111712054456300_REF8","doi-asserted-by":"crossref","unstructured":"Andrews RK, Lopez JA, Berndt MC. Molecular mechanisms of platelet adhesion and activation. Int J Biochem Cell Biol. 1997;29: 91-105.","DOI":"10.1016\/S1357-2725(96)00122-7"},{"key":"2019111712054456300_REF9","doi-asserted-by":"crossref","unstructured":"Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol. 1990;6: 217-246.","DOI":"10.1146\/annurev.cb.06.110190.001245"},{"key":"2019111712054456300_REF10","doi-asserted-by":"crossref","unstructured":"Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation: relationship to factor VIII procoagulant activity and antigen content. J Clin Invest. 1973;52: 2708-2716.","DOI":"10.1172\/JCI107465"},{"key":"2019111712054456300_REF11","doi-asserted-by":"crossref","unstructured":"Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67: 395-424.","DOI":"10.1146\/annurev.biochem.67.1.395"},{"key":"2019111712054456300_REF12","doi-asserted-by":"crossref","unstructured":"Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci U S A. 1998;95: 9524-9529.","DOI":"10.1073\/pnas.95.16.9524"},{"key":"2019111712054456300_REF13","unstructured":"Sadler JE. Von Willebrand disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York, NY: McGraw-Hill; 1989: 2171-2187."},{"key":"2019111712054456300_REF14","doi-asserted-by":"crossref","unstructured":"Jaffe EA, Hoyer LW, Nachman RL. Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest. 1973;52: 2757-2764.","DOI":"10.1172\/JCI107471"},{"key":"2019111712054456300_REF15","doi-asserted-by":"crossref","unstructured":"Jaffe EA, Hoyer LW, Nachman RL. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci U S A. 1974;71: 1906-1909.","DOI":"10.1073\/pnas.71.5.1906"},{"key":"2019111712054456300_REF16","doi-asserted-by":"crossref","unstructured":"Nachman R, Levine R, Jaffe EA. Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes. J Clin Invest. 1977;60: 914-921.","DOI":"10.1172\/JCI108846"},{"key":"2019111712054456300_REF17","unstructured":"Murine VWF cDNA Sequence. Available at: http:\/\/www.sheffield.ac.uk\/vwf\/murinecdna.html. Accessed May 13, 2006."},{"key":"2019111712054456300_REF18","doi-asserted-by":"crossref","unstructured":"Wagner DD, Olmsted JB, Marder VJ. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol. 1982;95: 355-360.","DOI":"10.1083\/jcb.95.1.355"},{"key":"2019111712054456300_REF19","doi-asserted-by":"crossref","unstructured":"Tjernberg P, Vos HL, Castaman G, Bertina RM, Eikenboom JC. Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues. J Thromb Haemost. 2004;2: 257-265.","DOI":"10.1111\/j.1538-7836.2003.00435.x"},{"key":"2019111712054456300_REF20","doi-asserted-by":"crossref","unstructured":"Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor: studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest. 1977;60: 390-404.","DOI":"10.1172\/JCI108788"},{"key":"2019111712054456300_REF21","doi-asserted-by":"crossref","unstructured":"Wise RJ, Dorner AJ, Krane M, Pittman DD, Kaufman RJ. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem. 1991;266: 21948-21955.","DOI":"10.1016\/S0021-9258(18)54729-3"},{"key":"2019111712054456300_REF22","doi-asserted-by":"crossref","unstructured":"Rosenberg JB, Foster PA, Kaufman RJ, et al. Intracellular trafficking of factor VIII to von Willebrand factor storage granules. J Clin Invest. 1998;101: 613-624.","DOI":"10.1172\/JCI1250"},{"key":"2019111712054456300_REF23","doi-asserted-by":"crossref","unstructured":"Haberichter SL, Fahs SA, Montgomery RR. von Willebrand factor storage and multimerization: two independent intracellular processes. Blood. 2000;96: 1808-1817.","DOI":"10.1182\/blood.V96.5.1808"},{"issue":"suppl 3","key":"2019111712054456300_REF24","first-page":"44","volume":"4","year":"1998","journal-title":"Haemophilia"},{"key":"2019111712054456300_REF25","doi-asserted-by":"crossref","unstructured":"Ahnstrom J, Berntorp E, Lindvall K, Bjorkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia. 2004;10: 689-697.","DOI":"10.1111\/j.1365-2516.2004.01036.x"},{"key":"2019111712054456300_REF26","doi-asserted-by":"crossref","unstructured":"Denis CV, Wagner DD. Insights from von Willebrand disease animal models. Cell Mol Life Sci. 1999;56: 977-990.","DOI":"10.1007\/s000180050487"},{"key":"2019111712054456300_REF27","doi-asserted-by":"crossref","unstructured":"Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 1999;6: 1258-1266.","DOI":"10.1038\/sj.gt.3300947"},{"key":"2019111712054456300_REF28","doi-asserted-by":"crossref","unstructured":"Zhang G, Gao X, Song YK, et al. Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther. 2004;11: 675-682.","DOI":"10.1038\/sj.gt.3302210"},{"key":"2019111712054456300_REF29","doi-asserted-by":"crossref","unstructured":"Krizek DR, Rick ME. A rapid method to visualize von Willebrand factor multimers by using agarose gel electrophoresis, immunolocalization and luminographic detection. Thromb Res. 2000;97: 457-462.","DOI":"10.1016\/S0049-3848(99)00196-6"},{"key":"2019111712054456300_REF30","doi-asserted-by":"crossref","unstructured":"Rathore V, Stapleton MA, Hillery CA, et al. PECAM-1 negatively regulates GPIb\/V\/IX signaling in murine platelets. Blood. 2003;102: 3658-3664.","DOI":"10.1182\/blood-2003-06-1888"},{"key":"2019111712054456300_REF31","doi-asserted-by":"crossref","unstructured":"Rathore V, Wang D, Newman DK, Newman PJ. Phospholipase C\u03b32 contributes to stable thrombus formation on VWF. FEBS Lett. 2004;573: 26-30.","DOI":"10.1016\/j.febslet.2004.07.048"},{"key":"2019111712054456300_REF32","doi-asserted-by":"crossref","unstructured":"Chuah MK, Schiedner G, Thorrez L, et al. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood. 2003;101: 1734-1743.","DOI":"10.1182\/blood-2002-03-0823"},{"key":"2019111712054456300_REF33","doi-asserted-by":"crossref","unstructured":"Barrowcliffe TW. Standardization of FVIII and FIX assays. Haemophilia. 2003;9: 397-402.","DOI":"10.1046\/j.1365-2516.2003.00773.x"},{"key":"2019111712054456300_REF34","doi-asserted-by":"crossref","unstructured":"Hubbard AR, Heath AB. Standardization of factor VIII and von Willebrand factor in plasma: calibration of the WHO 5th International Standard (02\/150). J Thromb Haemost. 2004;2: 1380-1384.","DOI":"10.1111\/j.1538-7836.2004.00838.x"},{"key":"2019111712054456300_REF35","doi-asserted-by":"crossref","unstructured":"Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med. 1999;5: 64-70.","DOI":"10.1038\/4751"},{"key":"2019111712054456300_REF36","doi-asserted-by":"crossref","unstructured":"Wang X, Cheng Q, Xu L, et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost. 2005;3: 695-702.","DOI":"10.1111\/j.1538-7836.2005.01236.x"},{"key":"2019111712054456300_REF37","doi-asserted-by":"crossref","unstructured":"Furlan M. von Willebrand factor: molecular size and functional activity. Ann Hematol. 1996;72: 341-348.","DOI":"10.1007\/s002770050184"},{"key":"2019111712054456300_REF38","doi-asserted-by":"crossref","unstructured":"Fukuda K, Doggett T, Laurenzi IJ, Liddington RC, Diacovo TG. The snake venom protein botrocetin acts as a biological brace to promote dysfunctional platelet aggregation. Nat Struct Mol Biol. 2005;12: 152-159.","DOI":"10.1038\/nsmb892"},{"key":"2019111712054456300_REF39","doi-asserted-by":"crossref","unstructured":"Liu J, Pestina TI, Berndt MC, Steward SA, Jackson CW, Gartner TK. The roles of ADP and TXA in botrocetin\/VWF-induced aggregation of washed platelets. J Thromb Haemost. 2004;2: 2213-2222.","DOI":"10.1111\/j.1538-7836.2004.01023.x"},{"key":"2019111712054456300_REF40","doi-asserted-by":"crossref","unstructured":"Brinkhous KM, Sandberg H, Garris JB, et al. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A. 1985;82: 8752-8756.","DOI":"10.1073\/pnas.82.24.8752"},{"key":"2019111712054456300_REF41","doi-asserted-by":"crossref","unstructured":"Ewenstein BM. von Willebrand's disease. Annu Rev Med. 1997;48: 525-542.","DOI":"10.1146\/annurev.med.48.1.525"},{"key":"2019111712054456300_REF42","doi-asserted-by":"crossref","unstructured":"Turecek PL, Gritsch H, Pichler L, et al. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. Blood. 1997;90: 3555-3567.","DOI":"10.1182\/blood.V90.9.3555"},{"key":"2019111712054456300_REF43","doi-asserted-by":"crossref","unstructured":"Motto DG, Chauhan AK, Zhu G, et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005;115: 2752-2761.","DOI":"10.1172\/JCI26007"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/108\/3\/862\/1282231\/zh801506000862.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/108\/3\/862\/1282231\/zh801506000862.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T03:40:32Z","timestamp":1627270832000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/108\/3\/862\/22360\/Correction-of-a-murine-model-of-von-Willebrand"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,1]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,8,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-06-2330","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,1]]}}}